Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

NCT01469793 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01469793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01469793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
December 31, 2015
Enrollment
71 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer